​Change to medical policy on Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®)

August 30, 2022

​Effective November 28, 2022, Independence Blue Cross and Independence Administrators will update their medical policy on Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®) for Commercial members.

Step therapy for the prevention and treatment of postoperative nausea and vomiting will be covered for individuals with a documented failure, contraindication, or intolerance to generic formulations of 5-HT3 antagonists (e.g., granisetron, ondansetron, palonosetron).

For more information, view the policy notification, which was published on August 30, 2022.